Axicabtagen-Ciloleucel (3, reassessment) (Yescarta®) – Diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma, after at least 2 prior therapies

Characteristics

Start date 15.05.2022
Resolution 03.11.2022
INN Axicabtagen-Ciloleucel
Brand name Yescarta®
Pharm. company Gilead Sciences GmbH
G-BA procedure ID 2022-05-15-D-820
ATC code L01XX70
ICD-10 codes C83.3Diffuse large B-cell lymphoma, C85.1Unspecified B-cell lymphoma
Therapeutic area Oncological diseases ORPHAN
Reason for procedure Reassessment: G-BA limitation
Original resolution: Axicabtagen-Ciloleucel (02.05.2019)
Regulatory status ATMP (CAR-T)

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Yescarta is used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) after two or more systemic therapies.

Subpopulation Indication Comparator
a) Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more systemic therapies – (Orphan drug)
b) Adults with relapsed or refractory primary mediastinal large B cell lymphoma (PMBCL) after two or more systemic therapies. – (Orphan drug)

9. Associated procedures



<< List of all resolutions

Log in to read more ...

The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.